

Tinea Versicolor Treatment Market is expected to reach USD 1107.9 million by 2023

Tinea Versicolor treatment market information, by diagnosis (wood lamp (black light) examination), by treatment, by end user- global forecast till 2023

PUNE, MAHARASHTRA, INDIA, July 25, 2017 /EINPresswire.com/ -- Market Highlights



Major Key Players are
Astellas Pharma US, Inc.
(Japan), Bayer AG (German),
Enzon Pharmaceuticals, Inc.
(US), Galderma S.A.
(Switzerland), Gilead (US),
Novartis AG , Pfizer Inc. (US),
”

Market Research Future

The global [tinea versicolor treatment](#) market has been evaluated as a moderately growing market and it is expected to continue growing in the near future. Tinea versicolor is common yeast infection of skin. The prevalence rate is higher in tropical areas and frequency is more during the summer. Increasing prevalence of various skin diseases are key factor for market growth. Some other major factors like increasing awareness, new drug development, clinical trials and approvals, and rising demand from emerging markets of Asia and South America are also driving the global tinea versicolor market.

The market for Tinea Versicolor treatment was around USD 685.4 million in 2016 and is expected to reach USD 1107.9 million by 2023 which is a projected CAGR of 7.1%.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3878

Major players in market:

- Astellas Pharma US, Inc. (Japan),
- Bayer AG (German),
- Enzon Pharmaceuticals, Inc. (US),
- Galderma S.A. (Switzerland),
- Gilead (US),
- Novartis AG (Switzerland),
- Pfizer Inc. (US),
- Taro Pharmaceutical Industries Ltd. (US),
- Teva Pharmaceutical Industries Ltd. (Israel),
- Valeant (Canada),

Regional Analysis:

Considering the global scenario of the tinea versicolor treatment market, there are four main regions, America, Europe, Asia Pacific, and Middle East and Africa. The Americas is holding largest market share. The Americas mainly include North America and South America. North America is very important and highest revenue generator market for tinea versicolor treatment. Asia Pacific is second largest and fastest growing market. Some major factors like increasing awareness of the disease,

developing healthcare sector, and rising healthcare expenditure are driving the growth for Asia Pacific tinea versicolor treatment market. Europe tinea versicolor treatment is also growing significantly. Germany, UK, and France are the major markets while Eastern European tinea versicolor treatment market is also growing. Middle East & Africa tinea versicolor treatment market is expected to have limited growth mainly due to lack of awareness of the disease, and limited access to the healthcare facilities. Due to developed healthcare infrastructure and high expenditure on healthcare, Middle East is dominating region as compared to Africa.

Taste the market data and market information presented through more than 60 market data tables and figures spread over 83 pages of the project report. Avail the in-depth table of content TOC & market synopsis on "[Tinea Versicolor Treatment Market Research Report–Global Forecast to 2023.](https://www.marketresearchfuture.com/reports/tinea-versicolor-treatment-market-3878)"

Report Details @ <https://www.marketresearchfuture.com/reports/tinea-versicolor-treatment-market-3878>

Segmentation:

Global tinea versicolor treatment market has been segmented on the basis of diagnosis which comprise physical exam, imaging tests, and others. Imaging test is sub-segmented into wood lamp (black light) examination, microscopy using Potassium Hydroxide (KOH), fungal culture, skin biopsy, and others. Skin biopsy is sub-segmented into shave biopsy, punch biopsy, excisional biopsy, and others.

On the basis of treatments, the market has been segmented into antifungal shampoos, antifungal creams, drugs, and others. Antifungal shampoos are sub-segmented into selenium sulfide (selsun) 2.5 percent shampoo, ciclopirox (Ioprox, penlac) shampoo, ketoconazole (ketoconazole, nizoral, others) shampoo, and others. Antifungal creams are sub-segmented into Selenium sulfide (Selsun) 2.5 percent lotion, Ciclopirox (Loprox, Penlac) cream or gel, Ketoconazole (Ketoconazole, Nizoral, others) cream or gel, and others. Drugs are further sub-segmented into fluconazole (diflucan) tablets or oral solution, and others.

On the basis of end user, it is segmented into dermatology hospital and clinics, medical research centers, academic institutes, and others.

Table of Content

1. Report Prologue
 2. Introduction
 - 2.1 Definition
 - 2.2 Scope of the Study
 - 2.2.1 Research Objective
 - 2.2.2 Assumptions
 - 2.2.3 Limitations
 - 2.3 Market Structure
 - 2.4. Market Segmentation
 3. Research Methodology
 - 3.1 Research Process
 - 3.2 Primary Research
 - 3.3 Secondary Research
 - 3.4 Market Size Estimation
 - 3.5 Forecast Model
 4. Market Dynamics
- Continued....

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:

Name: Akash Anand

Organization: Market Research Future

Address: Market Research Future Office No. 524/528,

Phone: +1 646 845 9312

Email: akash.anand@marketresearchfuture.com

Akash Anand

Market Research Future

+1-646-845-9349 (US) / +44 208 133 9349 (UK)

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.